|Table of Contents|

Application analysis of a simple and practical molecular typing method of endometrial cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 21
Page:
4115-4120
Research Field:
Publishing date:

Info

Title:
Application analysis of a simple and practical molecular typing method of endometrial cancer
Author(s):
LI Sandong1; QIAN Wenping1; WANG Jintao1; ZHANG Lei1; LIU Min2
1.Pathology Center,Youyi Clinical Laboratories of Shaanxi,Shaanxi Xi’an 710065,China;2.Basic Laboratory of Pathology,Shaanxi Provincial Cancer Hospital,Shaanxi Xi’an 710061,China.
Keywords:
endometrial carcinoma; molecular classification; immunohistochemistry; clinicopathological characteristics
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2024.21.018
Abstract:
Objective:To explore a simplified and practical molecular typing method for endometrial cancer(EC),and its relationship with the clinicalpathological features.Methods:110 cases of EC diagnosed in our pathology center from January 2020 to May 2023 were collected for analysis，using immunohistochemical staining to clarify molecular classification，and analyzing the clinicopathological characteristics of each molecular subtype.The surgical methods included total hysterectomy with double appendages and pelvic lymph node dissection.Results:Among the 110 cases of EC,immunophenotypes were divided into three groups based on immunohistochemical results.There were 58 cases(52.73%) in the MSI-H group,and 4 cases(3.64%) in the p53abn group,and 48 cases(43.64%) in the p53wt group.Among the three molecular subtypes,MSI-H and p53wt were not associated with age,FIGO pathological grading,FIGO staging,depth of muscular infiltration,vascular infiltration,and lymph node metastasis in EC patients(all P＞0.05).p53abn was associated with age,FIGO staging,depth of tumor muscle invasion,vascular infiltration,and lymph node metastasis in EC patients(all P＜0.05),but not with FIGO pathological grading of EC(P＞0.05).Comparative analysis showed that the molecular typing of the three groups was related to the age,FIGO pathological grading,FIGO staging,vascular infiltration,and lymph node metastasis in EC patients(all P＜0.05),and not to the depth of tumor muscle invasion of EC(P＞0.05).Conclusion:The simplified method of immunohistochemistry can serve as an effective approach for molecular typing of endometrial cancer．And it’s objectivity and repeatability can provide more precise information to clinical practice and can also provide equivalently important information for the diagnosis of molecular subtypes,and at the same time，providing scientific basis for the selection of treatment plans for EC patients．

References:

［1］JESSICA MA,ALICIA LC,TJALLING B.The rise of a novel classification system for endometrial carcinoma,integration of molecular subclasses［J］.J of Pathol，2018,244(5):538-549.
［2］KANDOTH C,SCHULTZ N,CHERNIACK AD,et al.Integrated genomic characterization of endometrial carcinoma［J］.Nature,2013,497(7447):67-73.
［3］SINGH N,PISKORZ AM,BOSSE T,et al.p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies［J］.J Pathol,2020,250(3):336-345.
［4］STELLOO E,NOUT RA,OSSE EM,et al.Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the porteccohorts［J］.Clin Cancer Res,2016,22(16):4215-4224.
［5］RAFFONE A,TRAVAGLINO A,RAIMONDO D,et al.Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma［J］.Gynecol Oncol,2021,161(2):621-628.
［6］PARRA-HERRAN C,LEMER-ELLIS J,XU B,et al.Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups［J］.Mod Pathol,2017,30(12):1748-1759.
［7］杜宁宁,刘岩,任彩霞,等.癌症基因组图谱子宫内膜癌分子分型在子宫内膜样癌中的临床应用探索［J］.中华病理学杂志,2019,48(8):596-603.DU NN,LIU Y,REN CX,et al.Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma［J］.Chinese Journal of Pathology,2019,48(8):596-603.
［8］KOMMOSS S，MC-CONECHY MK，KOMMOSS F，et al.Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series［J］.Ann Oncol，2018，29（5）:1180-1188.
［9］PAKISH JB,ZHANG Q,CHEN Z,et al.Immune microenvironment in microsatellite instable endometrial cancers:Hereditary or sporadic origin matters［J］.Clin Cancer Res,2017,23(15):4473-4481.
［10］STELLOO E,JANSEN AML,OSSE EM,et al.Practical guidance for mismatch repair-deficiency testing in endometrial cancer［J］.Ann Oncol,2017,28(1):96-102.
［11］赵宏喜，李艳红，谢丽，等.子宫内膜癌的流行病学特点及其转移的危险因素分析［J］.现代肿瘤医学，2017，25（23）:3803-3805.ZHAO HX,LI YH,XIE L,et al.Analysis of the epidemiological characteristics and the risk factors of metastasis of endometrial carcinoma［J］.Modern Oncology，2017，25（23）:3803-3805.
［12］王雅迪，于风胜，刘海梅,等.特殊类型子宫内膜癌的临床特征及预后分析［J］.实用妇产科杂志,2020,36(8):615-620.WANG YD，YU FS，LIU HM，et al.Clinical features and prognosis analysis of special types of endometnal carcinoma［J］.Journal of Practical Obstetrics and Gynecology,2020,36(8):615-620.
［13］赵立蓥，王玲，张肖肖，等.子宫内膜癌基因分型的研究进展［J］.现代肿瘤医学，2018，26（22）:3675-3678.ZHAO LY,WANG L,ZHANG XX，et al.The molecular classification of endometrial carcinoma［J］.Modern Oncology，2018，26（22）:3675-3678.
［14］HOANG LN,KINLOCH MA,LEO JM,et al.Interobserver agreement in endometrial carcinoma histotype diagnosis varies depending on the cancer genome atlas(TCGA)-based molecular subgroup［J］.Am J Surg Pathol,2017,41(2):245-252.
［15］GOEBEL EA,VIDAL A,MATIAS-GUIU X,et al.The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics:Past,present and future［J］.Virchows Arch,2018,472(6):885-896.
［16］TALHOUK A,MCCONECHY MK,LEUNG S,et al.A clinically applicable molecular-based classification for endometrial cancers［J］.Br J Cancer,2015,113(2):299-310.
［17］孙丽丽，刘格丹，贾楠，等.不同分子分型的子宫内膜癌临床病理特征分析［J］.肿瘤预防与治疗,2022,35(5):435-441.SUN LL,LIU GD,JIA N,et al.Clinicopathological features of endometrial cancer with different molecular types［J］.Journal of Cancer Control and Treatment,2022,35(5):435-441.
［18］EVA COLL-DELA R,ELENA MG,GUNNAR D，et al.Prognostic biomarkers in endometrial cancer:A systematic review and meta-analysis［J］．J Clin Med，2020，9(6):1900-1920．
［19］KIM MK,SO KA,CHUN YK,et al.Clinicopathologic significance of mismatch repair protein expression in endometrioid endometrial cancer［J］.Taiwan J Obstet & Gyne,2023,62(5):724-728.
［20］SAHIN IH，AKCE M，ALESEO，et al．Immune checkpoint inhibitors for the treatment of MSI-H／MMR-D colorectal cancer and a perspective on resistance mechanisms［J］.Br J Cancer，2019，121(10):809-818．
［21］RAFFONE A，TRAVAGLINO A，MASCOLO M，et a1．TCGA molecular groups of endometrial cancer:Pooled data about prognosis［J］.Gynecol Oncol，2019，155(2):374-383．
［22］晋薇,王利群,刘有,等.子宫内膜癌组织中 MMR 蛋白表达及 MLH1 基因甲基化的临床意义［J］.中华病理学杂志,2018,53(12):823-830.JIN W,WANG LQ,LIU Y,et al.Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer［J］.Chinese Journal of Pathology,2018,53(12):823-830.
［23］DOBRZYCKA B,TERLIKOWSKA KM,KOWALCZUK O,et al.Prognosis of stage I endometrial cancer according to the FIGO 2023 classification taking into account molecular changes［J］.Cancers,2024,16(2):390-405.
［24］彭娟，熊中堂，陈辉，等.PALB2和p53 在Ⅱ型子宫内膜癌中的表达及意义［J］.广东医学，2018,39(2):238-243.PENG J,XIONG ZT,CHEN H,et al.The expression and significance of PALB2 and p53 in type Ⅱ endometrial cancer［J］.Guangdong Medical Journal，2018,39(2):238-243.
［25］TALHOUK A,MCCONECHY MK,LEUNG S,et al.Confirmation of ProMisE:A simple,genomics-based clinical classifier for endometrial cancer［J］.Cancer,2017,123(5):802-813.
［26］URICK ME,BELL DW.Clinical actionability of molecular targets in endometrial cancer［J］.Nat Rev Cancer,2019,19(9):510-521.
［27］JAMIESON A,THOMPSON EF,HUVILA J,et al.Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases［J］.Gynecol Oncol,2022,165(2):376-384.

Memo

Memo:
-
Last Update: 2024-09-30